First-in-Human trial tests novel injection to fight diabetic vision loss
NCT ID NCT07228559
Summary
This is an early-stage study to check if a new drug called avoralstat is safe when injected into the eye of people with diabetic macular edema (DME), a condition that causes vision loss. The study will enroll 9 adults with DME to receive a single injection at one of three dose levels and be followed for 24 weeks. The main goal is to see how well the treatment is tolerated, while also looking for early signs that it might reduce retinal swelling and help vision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA (DME) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigative Site 1
RECRUITINGSydney, New South Wales, Australia
-
Investigative Site 2
RECRUITINGSydney, New South Wales, Australia
-
Investigative Site 3
RECRUITINGSydney, New South Wales, Australia
-
Investigative Site 4
RECRUITINGAdelaide, South Australia, Australia
-
Investigative Site 5
RECRUITINGMelbourne, Victoria, Australia
-
Investigative Site 6
RECRUITINGSacramento, California, 95825, United States
-
Investigative Site 7
RECRUITINGKaty, Texas, 77494, United States
-
Investigative Site 8
RECRUITINGThe Woodlands, Texas, 77384, United States
Conditions
Explore the condition pages connected to this study.